Skip to content

Editors

Harry Cassin
Publisher and Editor

Andy Spalding
Senior Editor

Jessica Tillipman
Senior Editor

Bill Steinman
Senior Editor

Richard L. Cassin
Editor at Large

Elizabeth K. Spahn
Editor Emeritus

Cody Worthington
Contributing Editor

Julie DiMauro
Contributing Editor

Thomas Fox
Contributing Editor

Marc Alain Bohn
Contributing Editor

Bill Waite
Contributing Editor

Shruti J. Shah
Contributing Editor

Russell A. Stamets
Contributing Editor

Richard Bistrong
Contributing Editor

Eric Carlson
Contributing Editor

Posts Tagged: Glaxo

Ex In-House Lawyer Re-indicted

The former associate general counsel of GlaxoSmithKline who won dismissal without prejudice of an obstruction and false statement indictment last month has been re-indicted.

The DOJ again charged Lauren Stevens with four counts of making false statements, one count of obstruction of justice, and one count of falsifying and concealing documents related to Glaxo’s promotion of the anti-depressant drug for weight loss, which hadn’t been approved by the Food and Drug Administration.… Continue Reading

The Novartis Speakers Bureau

Last week, Novartis agreed to pay a $185 million criminal fine for off-label marketing of the epilepsy drug Trileptal, and $237.5 million to resolve civil allegations over kickbacks paid to doctors to prescribe Trileptal and five other drugs.… Continue Reading

Watching For Whistleblowers

In its quarterly report released August 9, SciClone Pharmaceuticals, Inc. said it received an SEC subpoena and a letter from the DOJ investigating the “sale, licensing and marketing of its products in foreign countries, including China.”… Continue Reading

Helping Doctors Cheat

From an August 19 AP story: Drugmaker GlaxoSmithKline used a sophisticated ghostwriting program to promote its antidepressant Paxil, allowing doctors to take credit for medical journal articles mainly written by company consultants, according to court documents obtained by the Associated Press.Continue Reading